With the $1bn deal to transfer its US dermatology and orals solids operations to Aurobindo still awaiting completion, Sandoz is expanding its portfolio of sterile injectables - a key area of focus for the company - by acquiring the rights to two products from BE Pharmaceuticals.
Sandoz is continuing to show its appetite for sterile injectables and hospital drugs in the US by acquiring the rights to two mature generic injectables in the market for an undisclosed fee.
From Swiss player BE Pharmaceuticals, Sandoz will acquire the rights to generics of Merck’s Cubicin (daptomycin) 500mg and Emend (fosaprepitant...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
